Bioverge is a financial technology and investment platform bringing science fiction to life. We provide access to accredited investors, family offices, registered investment advisors, and others to invest alongside us and other top institutions in highly-vetted healthcare startups. We offer a variety of investment options, personalized to the unique needs of our investors including deal-by-deal investments, Access Funds, and Thematic Funds focused on specific technologies or diseases.
External link for Bioverge Ventures
237 Kearny St
San Francisco, California 94108, US
Bioverge Ventures reposted this
Notable is harnessing our predictive medicine platform to build a pipeline of novel therapeutics. By matching the right drug with the right patient, we aim to increase the clinical response rate of the therapeutics in our pipeline while reducing the risk, time and cost of development. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline
Bioverge Ventures reposted this
We are thrilled to announce the closing of our $4.2M initial funding round. A special thanks to Safar Partners, who led this round, and our other visionary investors who appreciate the tremendous power of our unique approach. We believe that our proprietary tools leveraging the natural function of CRISPR and demystifying the virome will unlock the potential of beneficial bacterial products addressing a broad range of medical and other applications, We are excited about our progress as we embark on this next stage of our growth. For more information see https://lnkd.in/e9gFSkwZ
Bioverge Ventures reposted this
Venture Capital ◆ Angel Club ◆ Accelerator | Healthcare, Biotech, Life Science, Medtech
🚀 Meet Our Advisors! We are excited to highlight that Neil Littman, Founding Partner of Bioverge Ventures and Partner of Riverine Ventures, as one of the esteemed advisors in our #H7 accelerator program. 👉 We are open for application for the 2024 Cohort of H7 Healthcare Accelerator, powered by H7 BioCapital. Early Bird Applications are open until 💥 July 20th 💥! 🦄 Apply for the Program: https://shorturl.at/TfJdB 🦄 Apply to Become Advisor: https://lnkd.in/eSbGpX28 📅 Early Bird Deadline: July 20th, 2024 🎯 About H7 Accelerator Program: https://lnkd.in/g3ycA8eE ------- 🎯Get to know our top-tier accelerator advisor - Neil Littman "Neil Littman, M.S. is Founder & CEO of Bioverge Ventures, a venture capital firm exclusively dedicated to investing in #earlystage, #cuttingedge #healthcare companies. Bioverge’s investment thesis is focused on companies spanning the intersection of health + tech that are utilizing advances in technology to modernize healthcare, from bench-to-bedside." "Previously, Neil was Vice President of Business Development at Notable Labs, an oncology startup and Bioverge portfolio company, where he led the development of global corporate partnerships and contributed to the strategic vision of Notable as part of the Senior Leadership Team. Neil oversaw business development at Notable through the successful completion of the company’s $40 million Series B and was instrumental in negotiating multiple terms sheets to in-license clinical stage oncology assets." 🌷Apply now to learn invaluable insights from Neil Littman get connected with our 100+ industrial leading experts, pitch to top #investors, and scale your #startup! 🥳 Once you're selected for #H7 accelerator cohort, you'll be part of the #H7 community for life. Expand your business and expand your network with access to a talented group of founders, investors, mentors, and industry leaders. #accelerator #venturecapital #fundraising #healthcare #lifesciences #biotech #drugdevelopment #artificialintelligence #medicaldevices #hospitals #clinicaltrials #oncology #research #startup #founders #precisionmedicine #commercialization #sales
Bioverge Ventures reposted this
Our predictive medicine platform employs advanced technology, including flow cytometry and robotic automation, to bio-simulate treatment of each patient’s cancer at the cellular level. Our biological response database provides improved insight into patient response, helping us to identify promising drugs to develop into new therapeutics. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation
Bioverge Ventures reposted this
Can regular progress updates and reporting with investors make startups more successful? Bioverge Ventures CEO and and venture capitalist, Neil Littman, thinks it could be the case. Here are 4 Reasons why: 📌The Phenomenon of “𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐇𝐲𝐠𝐢𝐞𝐧𝐞” Startups that regularly report to their investors exhibit what's known as "company hygiene." ▶️This means they maintain a disciplined and organized approach to managing their business. In contrast, startups that don't have this practice often lack structure and focus, leading to potential chaos. ▶️Disciplined startups could perform better because they have clear processes and accountability in place. 📌𝐓𝐡𝐞 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐀𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞 If a startup hides its challenges, how is it supposed to get the support it needs? ▶️When there’s transparency, everyone wins. ▶️Investors stay informed and startups get to tackle their problems head-on. 📌𝐅𝐨𝐫𝐜𝐞𝐝 𝐑𝐞𝐟𝐥𝐞𝐜𝐭𝐢𝐨𝐧 ▶️Regular reporting forces startups to reflect on their progress. They get to analyze what’s working, what’s not, and identify the challenges ahead. ▶️This self-assessment becomes an opportunity to fine-tune strategies and decisions that would’ve otherwise been overlooked. It introduces a higher degree of intentionality. ▶️It’s a built-in mechanism for continuous improvement. 📌𝐏𝐫𝐨𝐚𝐜𝐭𝐢𝐯𝐞 𝐏𝐫𝐨𝐛𝐥𝐞𝐦-𝐒𝐨𝐥𝐯𝐢𝐧𝐠 ▶️Delaying action until a problem becomes critical is a sure path to disaster. Regular updates mean startups are constantly communicating their challenges and needs. ▶️Small problems get to stay small rather than spiraling out of control. – What do you think? Do startups who report regularly tend to perform better? Share your insights in the comments below 👇🏽 To dive deeper into this, tune into Part 2 of my conversation with Neil Littman: APPLE: https://lnkd.in/gXNPgxHm SPOTIFY: https://lnkd.in/gNtZMVrW #charmhealthinnovationchallenge #charmhealth #chic
Bioverge Ventures reposted this
🌱 Pragma Bio is excited to share our latest article "Decoding BGCs: Nature's Blueprint for Tomorrow's Medicines". Ever wondered what are Biosynthetic Gene Clusters (BGCs) and what is their role in medicine? 💊 💉 🤓 Dive into our blog post to explore how these clusters unlock nature's pharmacy, offering potential for groundbreaking drug discovery and far beyond. Join us at Pragma Bio as we navigate BGC exploration for a a better and healthier planet. 🌎 🌍 🌏 #inovation #biotech #BGC #Medicine #DrugDiscovery #biotech #techbio #microbiome #microbiology #syntheticbiology #ai #aiml #smallmolecules
Bioverge Ventures reposted this
As we approach the ASCO 2024 annual meeting, and look forward to presenting our newest poster, we would like to take this opportunity to revisit some of our past scientific posters & abstracts. Study Published in Neuro-Oncology Advances Highlights Innovative Approach to Personalized CNS Drug Delivery for Leptomeningeal Disease 2023 – A groundbreaking study, titled "Dynamic Control of CSF for Personalized CNS Drug Delivery for Leptomeningeal Disease," has been published in Neuro-Oncology Advances, Volume 5, Issue Supplement_3, in August 2023. Led by Priya Kumthekar, MD, and Hector Ribeiro Benatti, PhD, the research team includes Toloo Taghian, Seema Nagpal, William Gormley, William Baker, Rajan Patel, Emma Brown, Marcie Glicksman, and Heather Gray-Edwards. Their study introduces an innovative approach to drug delivery in central nervous system (CNS) diseases, particularly leptomeningeal disease, aiming to improve therapeutic outcomes. Effective treatment of brain metastases and leptomeningeal disease requires appropriate drug distribution within the CNS. However, inadequate drug bioavailability often contributes to poor patient outcomes. EnClear Therapies has developed a device that delivers intrathecal therapeutics using dynamic control of cerebrospinal fluid (CSF) flow through an external pump. This novel system has the potential to enhance drug delivery and improve treatment efficacy. The study investigates the intrathecal delivery of methotrexate using EnClear's system and assesses its impact on drug concentration in CNS tissue in sheep and non-human primates. Preliminary findings suggest promising results, highlighting the potential of this innovative approach to revolutionize CNS drug delivery. The publication in Neuro-Oncology Advances underscores the importance of advancing novel technologies to address unmet clinical needs in neuro-oncology and beyond. For media inquiries and further information about the study, please contact EnClear Therapies at https://lnkd.in/eX7MvQ_i. About Neuro-Oncology Advances: Neuro-Oncology Advances is a leading peer-reviewed journal dedicated to publishing high-quality research and advancements in the field of neuro-oncology. It serves as a platform for disseminating innovative findings that contribute to improving patient care and outcomes. The study "Dynamic Control of CSF for Personalized CNS Drug Delivery for Leptomeningeal Disease" is available online at DOI: https://lnkd.in/ew2v3uAH. Marcie GlicksmanRajan PatelKevin KalishAnthony DePasqua #PrecisionDosing #NeuroOnc #ASCO
Bioverge Ventures reposted this
Adopt the mindset of an investor. For deeper insights, tune into Bioverge Ventures CEO Neil Littman’s discussion on game changers in seed investing. What nuances should investors prioritize? How do they unearth top-notch investment prospects? Explore the latest episode of Digital Health Disruptors with Neil Littman to get more insights into the promising trends shaping the biotech industry and the opportunities it presents for the industry and aspiring entrepreneurs. https://lnkd.in/gdh2_gMU Listen to all episode of the Digital Health Disruptors Podcast here: https://lnkd.in/gM5R2n2Y #CharmHealth #DigitalHealthDisruptors #podcast #biotechinvesting #biotech #healthtechnology #investing
Bioverge Ventures reposted this
Proud of the team effort it took to get this partnership over the line. A special shoutout to Jack Castle and Andrew Whittle for leading the deal process, as well as our whole R&D team for developing a thoughtful and ambitious research plan. We look forward to working with Steven S Pullen and the wider Boehringer Ingelheim team to progress regenerative medicines for liver disease patients, a growing and underserved medical need. Onwards and upwards! 💪 Thanks to Ian Johnston at the Financial Times and Lei Lei Wu at Endpoints News for the coverage, below: - https://lnkd.in/e-fAa-Hw - https://lnkd.in/eneR9Jnh
🎉 Announcing our new partnership with Boehringer Ingelheim to discover and develop novel regenerative treatments for chronic liver disease! Our multi-year collaboration will focus on using our proprietary discovery platform – which combines advanced genomics, deep phenotyping and machine learning – and human-organ translational models to accelerate the development of novel targets for undertreated liver diseases, such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. The deal brings in up to $35m in upfront and near-term milestone payments, with late preclinical, clinical, regulatory and commercial milestones with the potential to exceed $1B, as well as tiered commercial royalties. Chronic liver disease (CLD) and associated cirrhosis accounts for approximately 1 million deaths per year. Currently there are no approved medicines for cirrhosis resulting from CLD and there is an urgent need for new effective treatment options. The partnership is part of Boehringer Ingelheim’s commitment to improving the lives of people living with liver diseases. Together we will continue to pioneer liver regeneration research, with a shared vision of reversing the progression of diseases that affect millions worldwide. Read our full announcement ➡️ https://lnkd.in/ePFjWumn #TeamOchre #biotech #genomics #LiverDisease
Explore the latest edition of Bioverge Monthly! This issue highlights pivotal trends in the biotech market, including rising inflation concerns and their impact on Federal Reserve decisions. Dive into how artificial intelligence is reshaping pharmaceuticals, and catch up on Bioverge Ventures' efforts to democratize groundbreaking healthcare technologies. Join us as we bring science fiction to life, one breakthrough at a time. Read more in our April newsletter! https://lnkd.in/gyQDAA2d